A phase I trial of CTX130, an allogeneic CD70-directed CAR-T therapy, demonstrated a 46.2% ORR in relapsed or refractory T-cell lymphoma, highlighting its translational potential in CD70-positive tumors [49]. This evidence concerns the gene CD70 and T-cell non-Hodgkin lymphoma.